LLY vs ONMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible financial health. With a negative Price-to-Book ratio of -15.47 and a Current Ratio of 0.43, ONMD is facing a severe liquidity crisis and possesses negative shareholder equity. While the reported revenue growth of 3326.90% is astronomical, it is offset by a negative gross margin (-37.01%) and massive operating losses, suggesting that growth is currently being achieved at an unsustainable cost. The combination of bearish insider activity and a total lack of profitability makes this a high-risk speculative asset.
Compare Another Pair
Related Comparisons
LLY vs ONMD: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and OneMedNet Corporation (ONMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.